



VIII. Symposium of Young Researchers on Pharmaceutical Technology, Biotechnology and Regulatory Science

28–30 January, 2026 – Szeged, Hungary

OP-27

DOI: [10.14232/syrptbrs.2026.52](https://doi.org/10.14232/syrptbrs.2026.52)

Development of a chlorpromazine containing dry powder inhaler for targeting systemic effect

Zsófia Ilona Pizsman, Petra Party, Rita Ambrus

Institute of Pharmaceutical Technology and Regulatory Affairs, University of Szeged, Szeged, Hungary



Dry powder inhalers (DPIs) are used to delivery drugs directly to the lungs. While primarily used in the treatment of respiratory diseases, such as asthma and COPD, they also offer potential for systemic drug delivery. With pulmonary delivery the liver's first-pass metabolism can be avoided, thereby reducing the required effective dose and potentially minimizing side effects.

Our aim was to develop a chlorpromazine-containing (CPZ) DPI using nano-spray drying with appropriate excipients. In addition to the active ingredient, we used pullulan and leucin as excipients to achieve adequate aerodynamic properties. To optimize the production protocol and minimize the number of samples in the testing phase we applied the Placket-Burman and Box-Behnken experimental designs during the preliminary experiments. The spray-drying was executed using the Büchi Nano Spray Dryer B90. We expected the finished DPI formulations to have spherically shaped, micro-sized particles and suitable aerodynamic properties.

In DPI, the particle size was determined by laser diffraction, the shape by scanning electron microscopy, the crystallinity of the materials by X-ray powder diffraction, the chemical structure by Fourier transform infrared spectroscopy, the *in vitro* aerodynamic properties by Andersen cascade impactor, and the cytotoxicity using the A549 cell line. During the *in vivo* experiments the DPI was administered into the lungs of male rats and the CPZ concentration in the lungs and systemic circulation was examined.

In conclusion, we successfully developed a highly optimized production process for CPZ-containing DPIs, achieving exceptionally high fine particle fraction (FPF>95%), precise deposition, and excellent aerodynamic properties (MMAD>2 μm).

Acknowledgement

This research work was conducted with the support of the National Research, Development and Innovation Office (NKFIH OTKA K_146148); the National Academy of Scientist Education Program of the National Biomedical Foundation and the University Research Scholarship Program (EKÖP-181 -SZTE) under the sponsorship of the Hungarian Ministry of Culture and Innovation.